Mirikizumab demonstrates efficacy up to 52 weeks in Crohn’s disease

Phase 2 data support the safety and efficacy of mirikizumab in patients with Crohn’s disease, according to results presented at UEG Week.“At UEG Week, Lilly presented the first disclosure of new 52-week efficacy and safety data from the phase 2 SERENITY study evaluating mirikizumab in patients with moderately to severely active Crohn’s disease, and results showed continued symptom improvement and endoscopic response and remission,” Lotus Mallbris, MD, PhD, vice president and global head of immunology product development at Lilly, told Healio Gastroenterology. “TheseRead More

Share on facebook
Share on twitter
Share on linkedin